Dr. Houber on the De-Escalation of Treatments for Breast Cancer

Jens Huober, MD
Published: Tuesday, Jun 06, 2017



Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Both escalation and de-escaltation will play a role in the future of breast cancer. There are ongoing trials investigating the de-escalation of radiotherapy, explains Houber.

However, there will also need to be scenarios of escalation in patients with triple-negative breast cancer. What is currently being investigated is adding to cisplatin-based chemotherapy to increase the efficacy.
 


Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Both escalation and de-escaltation will play a role in the future of breast cancer. There are ongoing trials investigating the de-escalation of radiotherapy, explains Houber.

However, there will also need to be scenarios of escalation in patients with triple-negative breast cancer. What is currently being investigated is adding to cisplatin-based chemotherapy to increase the efficacy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x